Psoriasis Market Size, Epidemiology, Trends, and Forecast 2025-2035

 The psoriasis market reached a value of USD 20.3 Billion across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 38.4 Billion by 2035, exhibiting a growth rate (CAGR) of 5.96% during 2025-2035.

A chronic autoimmune condition which manifests itself with red, itchy, scaly patches on knees, elbows, trunk, and scalp, Psoriasis is a skin disorder. It arises when the immune system misfires and causes the skin cells to regenerate at an accelerated pace. The proriasis market is growing significantly in 2025 owing to increasing disease awareness along with improved diagnostic rates and treatment technologies. The occurrence of psoriasis is on a steady increase globally. Its contributed factors include environmental elements, genetic make-up, lifestyle factors like smoking, and stress. Improved healthcare access is diagnosing more patients and hence reporting a larger number of cases. This is positive, not an increase in disease burden. As awareness increases, more patients seek medical attention and actively seek treatment, which helps make effective treatments available.

For years, psoriasis was treated using topical medications and phototherapy. Nevertheless, there has been a notable shift in the industry with the development of biologics-- therapies that specifically alter the immune system's functions. These biologics tend to increase precision in the treatment of moderate and severe psoriasis, leading to better results and reduced side effects. In 2025, the market is still mostly dominated by biologics, especially those which focus on certain interleukins involved in inflammation, which are commercially the most successful. Their success has also paved the way for accessible biosimilars, which are less expensive versions of biologics, thus allowing greater segments of the population to access treatment.

The increasing use of artificial intelligence and data analytics in dermatology is also a contributor to the market needs. Advanced tools powered by AI are being developed to enable the early detection of psoriasis by evaluating certain images of skin lesions. These technologies improve accuracy and the speed at which dermatologists can diagnose conditions, allowing them to tailor treatments to individual patients depending on the type and severity of their psoriasis.

In addition to other therapies, researchers are exploring complementary and alternative medicine approaches throughout various disciplines. Especially in particular parts of the world where advanced biologics are not readily accessible, herbal and plant-based topical formulations are being regarded for their safety and effectiveness. These products seek to relieve inflammation and aid in the healing of the skin without the detrimental effects harsh steroids may cause.

The development of digital health platforms and telemedicine has also helped broaden the market. Remote consultations with dermatologists are now possible, which other than improving the scope of service helps patients situated in rural or remote communities. The availability of chronic disease management applications allows users to monitor their symptoms, medication intake, and progress which promotes treatment adherence as well as monitoring.

Collaboration between pharmaceutical companies and technology innovators creates synergies that enhance diagnosis, patient education, and customization of treatment using AI. This has led to more effective and patient-centered treatment for psoriasis.

Request for a sample of this report: https://www.imarcgroup.com/psoriasis-market/requestsample

Countries Covered:

• United States

• Germany

• France

• United Kingdom

• Italy

• Spain

• Japan

Analysis Covered Across Each Country:

• Historical, current, and future epidemiology scenario

• Historical, current, and future performance of the Psoriasis market

• Historical, current, and future performance of various therapeutic categories in the market

• Sales of various drugs across the Psoriasis market

• Reimbursement scenario in the market

• In-market and pipeline drugs                                                                              

This report also provides a detailed analysis of the current psoriasis market drugs and late-stage pipeline drugs.

In-Market Drugs:

• Drug Overview

• Mechanism of Action

• Regulatory Status

• Clinical Trial Results

• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs:

• Drug overview

• Mechanism of action

• Regulatory status

• Clinical trial results

• Drug uptake and market performance

Competitive Landscape with key players:

The competitive landscape of the psoriasis market has been studied in the report with the detailed profiles of the key players operating in the market.

Ask the Analyst for Customization and Explore the Full Report with TOC: https://www.imarcgroup.com/request?type=report&id=7295&flag=A

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us:

 

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

 

Contact US:

 

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145